Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Meningococcal ACWY Polysaccharide Vaccine · 1 trial · 2 indications
Safety of the Novartis MenACWY conjugate vaccine and of a licensed meningococcal ACWY conjugate vaccine as measured by the number of subjects presenting at least one severe systemic reaction during the first 7 days following a single vaccination in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Novartis MenACWY Vaccine (19 to 55 Years) | EXPERIMENTAL | Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years |
| Licensed polysaccharide vaccine | ACTIVE_COMPARATOR | Licensed meningococcal ACWY polysaccharide vaccine |
| Licensed Conjugate Vaccine | ACTIVE_COMPARATOR | Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine |
| Novartis MenACWY Vaccine (56 to 65 Years) | EXPERIMENTAL | Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years |
| Name | Type | Description |
|---|---|---|
| Meningococcal ACWY Polysaccharide Vaccine | BIOLOGICAL | One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection. |
| MenACWY CRM (19 to 55 years) | BIOLOGICAL | One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age. |
| Meningococcal ACWY Conjugate Vaccine | BIOLOGICAL | One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection. |
| Novartis MenACWY Vaccine (56 to 65 Years) | BIOLOGICAL | One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age. |
Inclusion Criteria: * individuals who are 19-65 years of age inclusive and who, after the nature of the study has been explained have provided written informed consent * individuals who are available for all visits and telephone calls scheduled for the study; * individuals who are in good health E...
Meningococcal ACWY Polysaccharide Vaccine is an investigational vaccine developed by Novartis AG for protection against meningococcal meningitis. It is designed to stimulate an immune response against meningococcal serogroups A, C, W, and Y. The vaccine has been studied in a Phase 3 clinical trial involving 2,831 healthy adults.
Meningococcal ACWY Polysaccharide Vaccine is intended for the prevention of meningococcal meningitis and meningococcal infections. It targets disease caused by meningococcal serogroups A, C, W, and Y. The vaccine is being developed by Novartis AG and has completed a Phase 3 trial in healthy adults.
Meningococcal ACWY Polysaccharide Vaccine is developed by Novartis AG, which trades under the ticker NVS. Novartis conducted a Phase 3 study of the vaccine in Argentina and Colombia.
Meningococcal ACWY Polysaccharide Vaccine is in Phase 3 development. One Phase 3 trial has been completed, and no active trials are currently listed. The vaccine is investigational and has not been approved by the FDA.
Meningococcal ACWY Polysaccharide Vaccine has been evaluated in one completed Phase 3 clinical trial, NCT00474487. The study was titled "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults" and enrolled 2,831 participants in Argentina and Colombia.
The Phase 3 trial NCT00474487 was a randomized, double-blind, active-controlled study. It enrolled 2,831 healthy adults aged 19 years and older of all sexes. The trial assessed safety and immune response and has been completed.